GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Cyclically Adjusted PS Ratio

Genmab AS (OCSE:GMAB) Cyclically Adjusted PS Ratio : 9.27 (As of May. 29, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Cyclically Adjusted PS Ratio?

As of today (2025-05-29), Genmab AS's current share price is kr1379.50. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was kr148.89. Genmab AS's Cyclically Adjusted PS Ratio for today is 9.27.

The historical rank and industry rank for Genmab AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCSE:GMAB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.23   Med: 50.55   Max: 96.41
Current: 9.36

During the past years, Genmab AS's highest Cyclically Adjusted PS Ratio was 96.41. The lowest was 8.23. And the median was 50.55.

OCSE:GMAB's Cyclically Adjusted PS Ratio is ranked worse than
67.2% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs OCSE:GMAB: 9.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab AS's adjusted revenue per share data for the three months ended in Mar. 2025 was kr77.158. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr148.89 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted PS Ratio Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.46 47.06 35.47 19.98 10.67

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.08 14.14 12.27 10.67 9.00

Competitive Comparison of Genmab AS's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


;
;

Genmab AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genmab AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1379.50/148.89
=9.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=77.158/120.2000*120.2000
=77.158

Current CPI (Mar. 2025) = 120.2000.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.844 100.300 3.408
201509 4.565 100.200 5.476
201512 9.424 99.800 11.350
201603 2.857 100.200 3.427
201606 5.663 100.600 6.766
201609 5.901 100.200 7.079
201612 14.043 100.300 16.829
201703 4.047 101.200 4.807
201706 12.688 101.200 15.070
201709 5.065 101.800 5.980
201712 16.958 101.300 20.122
201803 10.959 101.700 12.953
201806 8.149 102.300 9.575
201809 9.605 102.400 11.275
201812 19.539 102.100 23.003
201903 9.534 102.900 11.137
201906 12.383 102.900 14.465
201909 15.929 102.900 18.607
201912 46.195 102.900 53.962
202003 13.549 103.300 15.766
202006 82.771 103.200 96.406
202009 26.040 103.500 30.242
202012 36.947 103.400 42.950
202103 23.597 104.300 27.194
202106 29.538 105.000 33.814
202109 34.475 105.800 39.167
202112 36.483 106.600 41.137
202203 32.554 109.900 35.605
202206 47.372 113.600 50.124
202209 61.601 116.400 63.612
202212 90.297 115.900 93.647
202303 43.811 117.300 44.894
202306 63.510 116.400 65.583
202309 70.791 117.400 72.479
202312 81.399 116.700 83.840
202403 63.340 118.400 64.303
202406 82.867 118.500 84.056
202409 87.229 118.900 88.183
202412 82.571 118.900 83.474
202503 77.158 120.200 77.158

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab AS  (OCSE:GMAB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genmab AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.